Pharma In Brief - Federal Court Considers Functional Antibody Claims Valid And ... Mondaq News Alerts (registration) Justice Hughes dismissed Janssen's allegation that claims 143 and 222 were overbroad, even though these claims were found to cover antibodies and methods that were not exemplified in the '281 Patent. STELARA® was held to infringe claims 143 and 222 ... |
